Evaluating outcomes in eosinophilic gastrointestinal disorders

A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-Reported Outcomes in Pediatric and Adult Patients With Eosinophilic Esophagitis (EoE), Gastritis (EoG), Enteritis (EoN) and Colitis (EoC)

Observational Children's Hospital Medical Center, Cincinnati · NCT02523118

This study is trying to find the best ways to measure how well people with eosinophilic gastrointestinal disorders are doing by looking at their symptoms and tissue samples over time.

Quick facts

Study typeObservational
Enrollment1350 (estimated)
Ages3 Years and up
SexAll
SponsorChildren's Hospital Medical Center, Cincinnati Academic / other
Locations19 sites (Phoenix, Arizona and 18 other locations)
Trial IDNCT02523118 on ClinicalTrials.gov

What this trial studies

This observational study aims to identify the best measures for assessing the health of individuals with eosinophilic gastrointestinal disorders (EGIDs) such as eosinophilic esophagitis, gastritis, gastroenteritis, and colitis. Participants aged 3 years and older will undergo routine endoscopies and/or colonoscopies, during which biopsies will be collected for analysis. The study will compare tissue samples with clinical symptoms and utilize standard questionnaires to evaluate patient well-being over time. Participants will be followed longitudinally to track changes in their condition and quality of life.

Who should consider this trial

Good fit: Ideal candidates include males and females aged 3 years and older diagnosed with eosinophilic gastrointestinal disorders exhibiting specific eosinophil counts in tissue samples.

Not a fit: Patients with a history of intestinal surgery (other than G tube placement) or those with identifiable causes for eosinophilia may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved methods for monitoring and managing eosinophilic gastrointestinal disorders.

How similar studies have performed: Other studies have explored similar observational approaches in eosinophilic disorders, indicating potential for success in this area.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Males or females 3 years of age and older
* Mucosal eosinophilia:

EoE ≥ 15 eosinophils/HPF in the distal or proximal esophagus EoG ≥ 30 eosinophils/HPF in 5 HPF\'s in the body and/or antrum EoN ≥ 53 eosinophils/HPF in the duodenum and/or ≥ 56 eosinophils/HPF in the jejunum and/or ileum EoC ≥ 84 eosinophils/HPF from the transverse or descending colon and/or ≥ 32 eosinophils/HPF from the rectosigmoid colon or a biopsy from any colonic location with ≥ 100 eosinophils/HPF

\- Presence of symptoms is required for patients who are newly diagnosed but not required for patients who were previously diagnosed.

Exclusion Criteria:

* History of intestinal surgery other than G tube placement
* Enrolled in a blinded investigational study at the time of the first study visit
* Have esophageal stricture (\<3mm)
* Have other identifiable causes for eosinophilia (except Inflammatory Bowel Disease): infections, Gastrointestinal (GI) cancer, other GI inflammatory disease (e.g., Ulcerative Colitis or Crohn\'s Disease)

Where this trial is running

Phoenix, Arizona and 18 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Eosinophilic Gastrointestinal DisordersEosinophilic EsophagitisEosinophilic GastritisEosinophilic GastroenteritisEosinophilic Colitis
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.